Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Alexion Pharmaceuticals will pay roughly $855 million to acquire Wilson Therapeutics, a Swedish biotech firm focused on treatments for rare diseases. The move comes as Alexion tries to refill its pipeline and right its business in anticipation of a drop in sales of its rare-disease treatment Soliris. The centerpiece of the all-cash purchase is WTX101, a copper-binding agent in Phase III studies to treat Wilson disease, a rare genetic disorder marked by accumulation of copper in the liver, brain, and eyes.
This article has been sent to the following recipient: